.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Merck
QuintilesIMS
Johnson and Johnson
Colorcon
US Department of Justice
Argus Health
Dow
Teva
Deloitte
Baxter

Generated: July 26, 2017

DrugPatentWatch Database Preview

Speciality European Company Profile

« Back to Dashboard

What is the competitive landscape for SPECIALITY EUROPEAN, and what generic alternatives to SPECIALITY EUROPEAN drugs are available?

SPECIALITY EUROPEAN has one approved drug.

There are three US patents protecting SPECIALITY EUROPEAN drugs.

There are fifty-nine patent family members on SPECIALITY EUROPEAN drugs in thirty-four countries.

Summary for Applicant: Speciality European

Patents:3
Tradenames:1
Ingredients:1
NDAs:1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Speciality European
PLENAXIS
abarelix
INJECTABLE;INTRAMUSCULAR021320-001Nov 25, 2003DISCNNoNo► Subscribe► SubscribeY ► Subscribe
Speciality European
PLENAXIS
abarelix
INJECTABLE;INTRAMUSCULAR021320-001Nov 25, 2003DISCNNoNo► Subscribe► SubscribeY ► Subscribe
Speciality European
PLENAXIS
abarelix
INJECTABLE;INTRAMUSCULAR021320-001Nov 25, 2003DISCNNoNo► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Speciality European

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Speciality European
PLENAXIS
abarelix
INJECTABLE;INTRAMUSCULAR021320-001Nov 25, 2003► Subscribe► Subscribe
Speciality European
PLENAXIS
abarelix
INJECTABLE;INTRAMUSCULAR021320-001Nov 25, 2003► Subscribe► Subscribe
Speciality European
PLENAXIS
abarelix
INJECTABLE;INTRAMUSCULAR021320-001Nov 25, 2003► Subscribe► Subscribe
Speciality European
PLENAXIS
abarelix
INJECTABLE;INTRAMUSCULAR021320-001Nov 25, 2003► Subscribe► Subscribe
Speciality European
PLENAXIS
abarelix
INJECTABLE;INTRAMUSCULAR021320-001Nov 25, 2003► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Premature patent expirations for SPECIALITY EUROPEAN

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
► Subscribe ► Subscribe

International Patent Family for Speciality European Drugs

Country Document Number Estimated Expiration
Australia5699198► Subscribe
Czech Republic301119► Subscribe
Israel180450► Subscribe
Canada2274847► Subscribe
Hungary0000299► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Speciality European Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2011 00004Denmark► SubscribePRODUCT NAME: ABARELIX, EVENTUELT I FORM AF ET FARMACEUTISK SALT; NAT. REG. NO/DATE: 44637 (DK) 20100827; FIRST REG. NO/DATE: DE 578900000 20050922
C0015France► SubscribePRODUCT NAME: ABARELIX, EVENTUELLEMENT SOUS FORME DE SEL PHARMACEUTIQUEMENT ACCEPTABLE; REGISTRATION NO/DATE IN FRANCE: 69026150 DU 20101126; REGISTRATION NO/DATE AT EEC: 57890.00.00 DU 20050922
90014-9Sweden► SubscribePRODUCT NAME: ABARELIX
C/GB11/006United Kingdom► SubscribePRODUCT NAME: ABARELIX, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: DE - 20050922; UK PL32828/001 20100917
00484Netherlands► SubscribePRODUCT NAME: ABARELIX, EVENTUEEL IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; NAT. REGISTRATION NO/DATE: RVG 104389 20101220; FIRST REGISTRATION: 57890.00.00 20050922
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Cipla
Deloitte
Colorcon
Mallinckrodt
Farmers Insurance
US Army
Medtronic
Fish and Richardson
Harvard Business School
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot